CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.

J Immunother Cancer · 2023 · PMC10432633 · PMID 37586770

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A highly significant and complete elimination of human B cells and lymphoma cells was observed in peripheral blood samples from mice in all CLN-978 treatment groups regardless of dose level or route of administration ( online supplemental figure S4 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.